Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,143
- Phase 21,065
- Phase 1821
- Phase 1/Phase 2445
- Phase 3424
- Phase 4238
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis141
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California494
- Maryland196
- Alabama175
- Florida143
- Arizona140
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT05768178RecruitingPhase 2/Phase 3
Vemurafenib plus cobimetinib for BRAF-mutant cancers
This trial tests whether combining two targeted cancer medicines—vemurafenib and cobimetinib—can treat adults whose tumors have a specific “BRAF V600” mutation. You may be screened with blood tests and a tissue biopsy before starting treatment.
BelfastAges 18 years+ - NCT05768529RecruitingPhase 1/Phase 2
Study drug U16 for relapsed or refractory CD20 lymphoma
This trial tests U16 in people with CD20-positive non-Hodgkin lymphoma that has come back or not responded after prior treatments. It may help your immune system attack the lymphoma, and researchers will check safety and early signs of benefit.
Changsha, HunanAges 18–70 - NCT05770037RecruitingPhase 2/Phase 3
Alectinib for ALK-positive cancers in teens and adults
This study tests whether alectinib can treat ALK-positive cancers in adults, teenagers, and children. It focuses on people whose cancer testing shows an ALK change, and who can start oral treatment and have a new tissue sample.
BelfastAges Any age - NCT05770102RecruitingPhase 2/Phase 3
Atezolizumab for cancers with high mutation or immune markers
This trial tests atezolizumab, a cancer immunotherapy, for people whose tumors have high mutation levels (TMB), or are “MSI-high,” or have CMMRD. It may help shrink cancer or slow its growth by boosting the immune system’s ability to recognize the tumor.
BelfastAges Any age - NCT05770544RecruitingPhase 2/Phase 3
Entrectinib for ROS1 fusion cancers with matching gene test
This trial studies entrectinib, a targeted pill, in people whose cancer has a specific gene change called ROS1 fusion. It may help by shrinking tumors that depend on this ROS1 gene switch, and the study requires starting with a new tissue sample and treatment monitoring.
BelfastAges Any age - NCT05772611Recruiting
Study of immune responses in brain autoimmune and nerve syndromes
This study looks at how the immune system works in certain neurological conditions, including autoimmune encephalitis and related nerve disorders. Researchers may use blood and/or spinal fluid samples, especially when antibodies are present or can’t be found, to better understand what’s driving the illness.
LyonAges 18 years+ - NCT05772637Recruiting
Testing bladder feeling in people with multiple sclerosis
This study checks how your bladder “sensation” works using bladder testing (including urodynamic testing) to better understand MS-related bladder problems. It may help researchers match bladder symptoms to what’s happening inside the bladder.
Paris, Choisir Une RégionAges 18–99 - NCT05773040RecruitingPhase 1
CAR T-cell therapy made from your own immune cells
This Phase 1 trial tests an “autologous” CAR T-cell treatment (made from your own T cells) that targets a cancer marker called CD79b in certain relapsed or hard-to-treat B-cell lymphomas. It’s designed to find a safe dose and see whether the treatment can shrink tumors and help control the lymphoma after prior therapies.
Houston, TexasAges 18 years+ - NCT05774548Recruiting
Study of PrEP use and its cost in HIV prevention
This study looks at how taking PrEP (medicine to prevent HIV) affects HIV prevention and how much it costs in real life. You may be able to join if you are HIV-negative and are interested in starting, currently using, or have used PrEP before.
Bangkok, BangkapiAges 18 years+ - NCT05775042RecruitingPhase 2
CM338 for immunoglobulin A kidney disease
This Phase 2 study tests CM338 to see if it can help people with immunoglobulin A (IgA) nephropathy, a kidney condition. You may be able to join if you meet age, medication, and health criteria and can follow study safety rules.
Beijing, Beijing MunicipalityAges 18–75 - NCT05776511Recruiting
Eye Movement Test for White Matter Brain Changes
This study tests whether a special eye-tracking camera can help diagnose the cause of white matter hypersignals—unusual bright spots seen on brain MRI. Researchers want to see if eye movements can reveal clues about what's causing these brain changes.
NiceAges 18 years+ - NCT05776979RecruitingPhase 2
Isatuximab plus lenalidomide after transplant for high-risk myeloma
This Phase 2 trial tests whether adding isatuximab and lenalidomide as long-term treatment after stem cell transplant can help keep high-risk multiple myeloma under control. It may help some people reduce the chance of the disease coming back after transplant.
Houston, TexasAges 18–72 - NCT05779605Recruiting
Online rehab for lymphoma survivors after chemotherapy
This trial tests a telerehabilitation (remote exercise/rehab) program for people with recent lymphoma or other blood cancers after chemotherapy. It aims to improve recovery and fitness while monitoring safety through an exercise test and check-ins.
BrnoAges 18 years+ - NCT05780034RecruitingPhase 1
Study drug AC676 for certain relapsed blood cancers
This Phase 1 trial tests AC676, a study medicine, for adults with certain B-cell blood cancers that have come back or did not respond to prior treatment. It may help people who have tried standard therapies and need new options.
Denver, ColoradoAges 18 years+ - NCT05780099Recruiting
Study of patients treated in internal medicine clinics
This observational study follows people receiving care in Internal Medicine at San Raffaele Hospital to better understand what kinds of conditions they have. It does not test a new treatment, but your information may help improve future care.
MilanAges 18 years+ - NCT05782335Recruiting
Study immune cell changes with Orencia in rheumatoid arthritis
This trial studies how Orencia (abatacept) affects your immune system’s T and B cells in people with rheumatoid arthritis. It may help researchers better understand who responds to Orencia and what immune changes happen over time.
New York, New YorkAges 18 years+ - NCT05783609RecruitingPhase 2
Epcoritamab and rituximab for untreated follicular lymphoma
This phase 2 trial tests whether a combination of epcoritamab plus rituximab can work as a first treatment for follicular lymphoma. It may help people whose lymphoma is causing symptoms or affecting organs, or who have bulky disease, by targeting the lymphoma cells.
Boston, MassachusettsAges 18 years+ - NCT05785156Recruiting
Quick test study to predict stroke and memory disease outlook
This study tests quick new methods to measure “slowed actions” in people with stroke or memory-related brain conditions. The goal is to see whether these quick tests can help predict future outcomes and guide care.
AmiensAges 40–85 - NCT05785299Recruiting
Testing home vs clinic introduction of milk for babies
This study compares introducing cow’s milk at home versus in a clinic for babies who may have a non-allergy type reaction to cow’s milk. It may help families learn the safest way to reintroduce milk when classic milk allergy tests are negative.
GroningenAges 1 month–1.5 years - NCT05785793Recruiting
Autoimmune hepatitis study for people in China
This study follows people with autoimmune hepatitis (a condition where the immune system attacks the liver) and requires key blood test results at diagnosis. It may help doctors better understand this disease and how it progresses in patients in China.
Shanghai, Shanghai MunicipalityAges 14 years+ - NCT05786235Recruiting
Pregnant people with or without antiphospholipid antibodies
This study is looking at pregnancy outcomes in people who are pregnant and either have antiphospholipid antibody syndrome (APS) or do not have APS but do have prior full-term pregnancies. It may help doctors understand risks and how to manage pregnancies in these groups.
MilanAges 18–45 - NCT05786547RecruitingPhase 3
Varenicline plus support to help quit tobacco in HIV care
This Phase 3 trial tests a quit-smoking program using varenicline (a medicine) plus additional support, for people with HIV who currently use tobacco. It may help you stop smoking or using tobacco and stay quit with safer, guided care.
Aurora, ColoradoAges 18 years+ - NCT05787574RecruitingPhase 2
Reducing inflammation before stem cell transplant in immune disorders
This Phase 2 study tests medicines that calm inflammation before the first stem cell transplant. It aims to make transplant safer and more effective for people with certain inherited immune regulation or inflammatory conditions.
San Francisco, CaliforniaAges Any age - NCT05787795Recruiting
Studying early risk signs for multiple sclerosis
This study looks at people who are at higher risk for multiple sclerosis (MS), to better understand early changes before MS is diagnosed. It may help doctors identify who is more likely to develop MS and how to monitor them sooner.
North Haven, ConnecticutAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,742 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.